Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | LNK001 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on LNK001, a putative chimeric antigen receptor (CAR) T-cell therapy targeting CA9 (CAIX) and ENPP3 (Jun 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| LNK001 | LNK 001|LNK-001 | Limited information is currently available on LNK001, a putative chimeric antigen receptor (CAR) T-cell therapy targeting CA9 (CAIX) and ENPP3 (Jun 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07564232 | Phase I | LNK001 Cyclophosphamide + Fludarabine | Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma | Not yet recruiting | USA | 0 |